about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

Clin­i­cal stud­ies for AB Sci­ence's all-pur­pose an­ti-in­flam­ma­to­ry drug grind to a halt as com­pa­ny flags po­ten­tial risk ...

4 years ago
R&D

No­var­tis scraps a slate of Beovu tri­als af­ter 4-week dos­ing turned up safe­ty is­sues — dash­ing hopes of de­thron­ing ...

4 years ago
R&D
Pharma

Lat­est news: Am­gen's land­mark OK for KRAS drug, in­side Ver­tex 3.0, the big hunt for CAR-T in sol­id tu­mors, and more

4 years ago
Weekly

Fra­zier re­loads with $1.4B to bet on 'growth buy­out' plays — near­ly dou­ble the last fund

4 years ago
Financing

As FDA clears re­l­u­golix for uter­ine fi­broids, My­ovant, Pfiz­er gear up to take on Ab­b­Vie in com­mer­cial ri­val­ry

4 years ago
Pharma
FDA+

No­vo Hold­ings, Vi­vo lead a record $200M raise for a Sin­ga­pore-based tools play­er with plans for a Boston hub, new ...

4 years ago
Financing
China

Eight bets in, Spain's Ys­ios of­fi­cial­ly ties a bow around €216M fund

4 years ago
Financing

Deaths of mon­keys spur clin­i­cal hold for rare dis­ease biotech's lead and on­ly drug — and a $95M cash in­fu­sion goes ...

4 years ago
FDA+

Days af­ter FDA clears C3 drug, Apel­lis spot­lights ex-US PhI­II win among pa­tients who haven't tak­en Soliris

4 years ago
R&D
Pharma

Re­searchers in biotech, acad­e­mia and Big Phar­ma are of­fer­ing puz­zle pieces to crack CAR-T for sol­id tu­mors. Will they ...

4 years ago
Cell/Gene Tx
In Focus

Rare dis­ease play­er that went pub­lic in biotech's go-go years merges with spe­cial­ty phar­ma in all-stock deal — at a ...

4 years ago
Deals

NGM con­cedes key fail­ure for their lead NASH drug, clos­ing the door on a piv­otal fol­lowup — and ask­ing an­a­lysts to ...

4 years ago
R&D

With its dengue vac­cine in the reg­u­la­to­ry queue, Take­da out­lines longterm fol­lowup da­ta that it says keep it out of ...

4 years ago
R&D

Lat­est news on J&J’s NSCLC ap­proval, Bris­tol My­ers Squibb’s big TIG­IT bet, #AS­CO21 and more

4 years ago
Weekly

Take­da tees up pri­or­i­ty re­view for sto­ried CMV drug from its $62B Shire buy­out

4 years ago
FDA+

Be the spark? Roche’s Spark sues fel­low gene ther­a­py de­vel­op­er blue­bird for ‘usurpa­tion’ of trade­mark

4 years ago
Cell/Gene Tx

#AS­CO21: Ab­b­Vie-part­nered Chi­nese biotech with first-in-class am­bi­tions show­cas­es ear­ly da­ta on CD73 an­ti­body

4 years ago
R&D

CMC holdup de­lays Io­vance fil­ing again — to 2022 — as FDA seeks more as­say da­ta for TIL ther­a­py

4 years ago
Cell/Gene Tx
FDA+

Sarep­ta touts clean da­ta for com­mer­cial grade Duchenne gene ther­a­py, clear­ing key hur­dle to PhI­II

4 years ago
R&D
Cell/Gene Tx

Eye­ing clin­i­cal proof-of-con­cept for HER3 drug, Am­gen-part­nered biotech scores $125M for pre­ci­sion an­ti­bod­ies

5 years ago
Financing

Sanofi, Glax­o­SmithK­line jump back in­to the PhI­II race for a Covid vac­cine — as the win­ners con­gre­gate be­hind the ...

5 years ago
R&D
Coronavirus

$DNA is once again on NYSE; FDA clears Soliris chal­lenger for the mar­ket; Flag­ship’s think­ing big again with eR­NA; ...

5 years ago
Weekly

Kept an ocean away from its sci­en­tif­ic ad­vi­sors, Shang­hai's Elpi­science keeps up the clin­i­cal progress, re­fu­els for ...

5 years ago
R&D

Af­ter go­ing down dif­fer­ent drug dis­cov­ery paths, Genen­tech vets re­unite at Fore­site Labs to map the 'pro­tein ...

5 years ago
Financing
Startups
First page Previous page 50515253545556 Next page Last page
A service from the Financial Times